Sutro Biopharma
Logotype for Sutro Biopharma Inc

Sutro Biopharma (STRO) investor relations material

Sutro Biopharma Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Sutro Biopharma Inc
Jefferies Global Healthcare Conference summary18 Nov, 2026

Pipeline strategy and platform

  • Since the pivot last March, the development plan accelerated from three clinical programs in three years to three in two years; two are in clinic, with a third expected to enter early next year.

  • Tissue Factor and integrin beta-6 were selected as complex targets to establish single-payload ADC performance and support later dual-payload development.

  • Cell-free engineering, tumor-cleavable β-glucuronidase linkers and non-natural amino acids enable component optimization, site-specific conjugation and tunable payload ratios.

  • The linker strategy is intended to reduce premature payload release and cytopenias; the platform can also support high drug-to-antibody ratios, including DAR16 without compromising PK.

STRO-004

  • Early clinical activity was reported across pancreatic, head and neck, and lung cancers in heavily pretreated U.S. patients; the August cohort included irinotecan exposure in all PDAC and CRC patients, with some exposed more than once.

  • Safety was described as manageable, with mostly grade 1–2 AEs, limited hematologic and target-related toxicity, and low discontinuation; mitigation for stomatitis and ocular AEs appeared manageable.

  • PK included a seven-day half-life, 98% DAR8 configuration and no observed free-payload spike; management expects this profile to reduce circulating free payload and related cytopenias.

  • A fuller efficacy update is planned for H1 2027, alongside dose expansion in an earlier-line population; dose escalation backfill cohorts target 10–12 patients per dose and indication.

  • Current dose escalation spans multiple doses and tumor types; management aims to build a more informative patient sample at optimized doses and may begin regulatory discussions as data mature.

STRO-006

  • STRO-006 targets integrin beta-6 and uses the same linker-payload design as STRO-004; broad expression across lung and head and neck cancers supports a basket approach.

  • Initial dosing is planned at 1.5 mg/kg, with management expecting to reach active dose levels sooner; initial data are guided for H2 2027.

  • After reaching active doses, the study may narrow its tumor basket to prioritize lung and head and neck cancers and maximize early activity signals.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Sutro Biopharma earnings date

Logotype for Sutro Biopharma Inc
38th Annual Healthcare Conference2 Dec, 2026
Sutro Biopharma
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Sutro Biopharma earnings date

Logotype for Sutro Biopharma Inc
38th Annual Healthcare Conference2 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Sutro Biopharma Inc. is a biotechnology company specializing in the discovery, development, and manufacturing of therapeutics aimed at treating cancer. The company leverages its proprietary cell-free protein synthesis platform, XpressCF, to design and produce novel, targeted antibody-drug conjugates (ADCs), bispecific antibodies, and other protein therapeutics. Sutro's focus is on creating therapies that precisely target and eliminate cancer cells while minimizing damage to healthy tissues, advancing treatment options for patients with difficult-to-treat cancers. The company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ.